A randomized phase II study of amifostine used as stem cell protectant in non-Hodgkin lymphoma patients receiving cisplatin-based salvage chemotherapy prior to stem cell transplant

Journal of Hematotherapy and Stem Cell Research

Volumn 10, Issue 6, 2001, Pages 887-893

  Emmanouilides, Christos ^a,b   Territo, Mary ^a,b   Andrey, Jeffrey ^a,b   Mason, James ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; CLADRIBINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FAMOTIDINE; FLUDARABINE; GRANISETRON; IFOSFAMIDE; MITOXANTRONE; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; APHERESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROTECTION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; NAUSEA; NONHODGKIN LYMPHOMA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0035682542     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581601317210980     Document Type: Article

References (37)

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
2. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
3. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study [see comments]
4. ESHAP is an active regimen for relapsing Hodgkin's disease
5. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma
6. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: A single-center study of 22 patients
7. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: Those transplanted with active CNS disease have a poor outcome - A report by the European Bone Marrow Transplant Lymphoma Registry
8. Management strategies for the hard-tomobilize patient
9. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma
10. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors
11. Radioprotection of mouse colony forming units-spleen against heavy-charged particle damage by WR 2721
12. Pharmacologic approaches to protection against radiation-induced lethality and other damage
13. Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro compared in comparison to the effects of thiosulfate and diethyldithiocarbamate
14. Protection from cellular oxidative injury and calcium intrusion by N-(2-mercaptoethy)-1,3-propanediamine, WR 1065
15. Protection of mouse bone marrow by WR-2721 after fractionated irradiation
16. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects
17. Carboplatin combined with Amifostine, a bone marrow protectant in the treatment of non-small cell lung cancer: A randomized phase II study
18. Pharmacologic approaches to protection against radiation-induced lethality and other damage
19. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: Amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery
20. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamidepurged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support
21. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
22. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
23. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation
24. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721
25. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity
26. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of nonsmall-cell lung cancer: A randomized phase II study
27. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy
28. Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma
29. WR1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
30. Use of amifostine in bone marrow purging
31. The potential role of amifostine (Ethyol) in haematological malignancies
32. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
33. Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug
34. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation
35. Amifostine (WR2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: A phase II study
36. Management strategies for the hard-to-mobilize patient
37. Economic analysis of Amifostine support for patients with advanced Head and Neck cancer: Preliminary results of a randomized phase II trial from Germany